Relmada Therapeutics Inc.
RLMD | NASDAQ
$4.21
+$0.05 (+1.20%)
Sep 22, 2026, 12:50 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -3.33 | -0.20 | -0.31 | -0.16 | -0.63 | -1.68 |
PEG Ratio | 0.07 | 0.01 | 0.01 | 0.01 | -0.01 | -0.01 |
PS Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
PB Ratio | 2.20 | 0.44 | 0.36 | 0.18 | 0.38 | 0.95 |
P/FCF Ratio | -4.16 | -0.30 | -0.60 | -0.25 | -0.86 | -3.59 |
P/OCF Ratio | -4.16 | -0.30 | -0.60 | -0.25 | -0.86 | -3.59 |
OCF/S Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Debt / Equity Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Quick Ratio | 14.62 | 4.45 | 8 | 12.26 | 14.83 | 9.37 |
Current Ratio | 14.62 | 4.45 | 8 | 12.26 | 14.83 | 9.37 |
Asset Turnover | n/a | n/a | n/a | n/a | n/a | n/a |
Interest Coverage | n/a | n/a | n/a | n/a | n/a | n/a |
Return on Equity | -66.33% | -225.15% | -115.74% | -111.83% | -60.38% | -56.31% |
Return on Assets | -61.05% | -174.56% | -101.27% | -102.71% | -56.31% | -50.31% |
Return on Invested Capital | -67.49% | -236.14% | -121.49% | -114.82% | -60.36% | -57.62% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Net Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Margin | n/a | n/a | n/a | n/a | n/a | n/a |
EBITDA Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove RLMD